Stocks and Investing Stocks and Investing
Fri, November 4, 2022

Tejas Savant Maintained (TXG) at Buy with Decreased Target to $64 on, Nov 4th, 2022


Published on 2024-10-27 23:56:14 - WOPRAI, Tejas Savant
  Print publication without navigation


Tejas Savant of Morgan Stanley, Maintained "10x Genomics, Inc." (TXG) at Buy with Decreased Target from $70 to $64 on, Nov 4th, 2022.

Tejas has made no other calls on TXG in the last 4 months.



There are 5 other peers that have a rating on TXG. Out of the 5 peers that are also analyzing TXG, 2 agree with Tejas's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Weinstein of "William Blair" Downgraded from Buy to Hold on, Friday, July 15th, 2022
  • Amit Hazan of "Goldman Sachs" Maintained at Hold with Decreased Target to $60 on, Thursday, July 14th, 2022


These are the ratings of the 3 analyists that currently disagree with Tejas


  • Matthew Sykes of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $25 on, Thursday, October 13th, 2022
  • Dan Brennan of "Cowen & Co." Maintained at Buy with Decreased Target to $50 on, Friday, July 15th, 2022
  • Derik De Bruin of "B of A Securities" Downgraded from Hold to Sell and Decreased Target to $35 on, Friday, July 15th, 2022

Contributing Sources